Filing Flows › Biofrontera (BFRI) › Q1 2026 › vs Q4 2025
Biofrontera (BFRI) Q1 2026 vs Q4 2025 (quarter over quarter)
Biofrontera's revenue fell $7.0M (-41%) from $17.1M in Q4 2025 to $10.1M in Q1 2026.
Biofrontera, Q1 2026: revenue $10.1M (+17% year over year), operating margin -42.8%, net loss $4.8M, operating cash flow −$70K. The chart draws each line against Q4 2025, the increases inside each band.
Every line
| Line | Q1 2026 | Q4 2025 | Change | % |
|---|---|---|---|---|
| Revenue | $10.1M | $17.1M | −$7.0M | -41% |
| Net loss | $4.8M | −$5.6M | $10.4M | — |
| Costs & expenses | $14.8M | $18.2M | −$3.3M | -18% |
| Operating costs | $14.4M | $12.5M | $1.9M | +15% |
| Interest & other, net | $432K | −$1.1M | $1.5M | — |
| Research & development | $900K | $787K | $113K | +14% |
| SG&A | $11.0M | $8.5M | $2.5M | +29% |
| Other operating costs | $2.5M | $3.2M | −$722K | -22% |
| Operating cash sources | $4.8M | −$5.6M | $10.4M | — |
| Depreciation & amortization | $55K | $36K | $19K | +53% |
| Share-based compensation | $342K | $289K | $53K | +18% |
| Working capital & other | $4.3M | −$8.3M | $12.6M | — |
| Cash used in operations | $70K | $2.4M | −$2.3M | -97% |
| Net loss absorbed | $4.8M | −$5.6M | $10.4M | — |
Questions
How much did Biofrontera's revenue grow quarter over quarter in Q1 2026?
Biofrontera's revenue fell $7.0M (-41%) from $17.1M in Q4 2025 to $10.1M in Q1 2026.